Failure of dibutyryl and 8-bromo-cyclic GMP to mimic the antagonistic action of carbachol on the positive inotropic effects of sympathomimetic amines in the canine isolated ventricular myocardium.
Effects of carbachol, dbcGMP and 8-bromo-cyclic GMP on the positive inotropic actions of sympathomimetic amines and dbcAMP were studied on the canine isolated right ventricular myocardium. Carbachol alone did not substantially change the developed tension of the muscle, but did markedly shift the dose response curve for isoprenaline on the developed tension to the right and depressed the maximal response to the drug in a concentration dependent manner. The positive inotropic action of phenylephrine was affected by carbachol in the same manner as that of isoprenaline. DbcGMP in concentrations of 10(-3) M and higher produced a significant increase in the developed tension. The positive inotropic action of dbcGMP was partly inhibited by a beta-adrenoceptor blocking agent, pindolol. In the presence of dbcGMP, isoprenaline produced an action similar to that seen in the control experiment, but this action was not maintained on such a steady state level as in the control. This rapid decline of the effect of isoprenaline in the presence of dbcGMP was prevented by adding ascorbic acid to the organ bath. The positive inotropic actions of phenylephrine and of dbcAMP were not substantially affected by dbcGMP. 8-Bromo-cyclic GMP in a concentration of 10(-4) M did not change either the basal developed tension or the positive inotropic actions of noradrenaline and of isoprenaline. The present results indicate that these cyclic GMP derivatives are not able to mimic the antagonistic action of cholinergic stimulation on the positive inotropic action of adrenergic stimulation on the positive inotropic action of adrenergic stimulation on the canine ventricular myocardium.
D000818:Animals; D003994:Bucladesine / Q000037:antagonists & inhibitors; D002217:Carbachol / Q000494:pharmacology*; D006152:Cyclic GMP / Q000031:analogs & derivatives* / Q000032:analysis / Q000494:pharmacology; D003995:Dibutyryl Cyclic GMP / Q000494:pharmacology*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005260:Female; D006352:Heart Ventricles / Q000187:drug effects; D066298:In Vitro Techniques; D007545:Isoproterenol / Q000037:antagonists & inhibitors; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects*; D009206:Myocardium / Q000032:analysis; D009638:Norepinephrine / Q000037:antagonists & inhibitors; D010656:Phenylephrine / Q000037:antagonists & inhibitors; D013268:Stimulation, Chemical; D013566:Sympathomimetics / Q000037:antagonists & inhibitors* / Q000494:pharmacology
D013566:Sympathomimetics; D010656:Phenylephrine; C016276:8-bromocyclic GMP; D003995:Dibutyryl Cyclic GMP; D003994:Bucladesine; D002217:Carbachol; D006152:Cyclic GMP; D007545:Isoproterenol; D009638:Norepinephrine